



# Board of Pharmacy

---

## e-News April 2025

---

### Board Issues Draft Rules on Remote Dispensing Pharmacies

**SB 95** (135th General Assembly), which was signed into law on January 8, 2025, authorizes the Ohio Board of Pharmacy to license and regulate remote dispensing pharmacies. The law, which goes into effect on April 9, 2025, requires the Board to adopt rules prior to the licensure of any remote dispensing pharmacies. To implement this new law, the Board is proposing the adoption of the following rules:

- Rule 4729:5-18-01 – Definitions – remote dispensing pharmacies.
- Rule 4729:5-18-02 – Licensure of remote dispensing pharmacies.
- Rule 4729:5-18-03 – Demonstration of need.
- Rule 4729:5-18-04 – Operation of a remote dispensing pharmacy.
- Rule 4729:5-18-05 – Personnel requirements.
- Rule 4729:5-18-06 – Technology requirements for a telepharmacy system.
- Rule 4729:5-18-07 – Security requirements for a remote dispensing pharmacy.

A copy of the proposed rules can be accessed by visiting:

[www.pharmacy.ohio.gov/RemoteRules](http://www.pharmacy.ohio.gov/RemoteRules)

Please be advised that any references to the Ohio Pharmacy Access Dashboard means the Pharmacy Deserts tab, which can be accessed here: [www.pharmacy.ohio.gov/trends](http://www.pharmacy.ohio.gov/trends)

Comments on the proposed rules will be accepted until the close of business on **Friday, May 9, 2025**. Please send all comments to the following email address:

[isabella.blankenship@pharmacy.ohio.gov](mailto:isabella.blankenship@pharmacy.ohio.gov)

---

### FDA Issues Guidance on the Compounding of Retatrutide

On April 3, 2025, the National Association of Boards of Pharmacy shared a letter from the U.S. Food and Drug Administration (FDA) regarding the legality of compounding prescription products containing retatrutide.

This letter clearly indicates that compounding prescription drug products with retatrutide is prohibited by all pharmacies compounding under either Section 503A or 503B of the Federal Food, Drug and Cosmetic Act (FD&C Act). A copy of the letter may be accessed here: [www.pharmacy.ohio.gov/FDAreta](http://www.pharmacy.ohio.gov/FDAreta).

Please be advised that any violation of the FD&C Act is considered a violation of Ohio law and may result in administrative sanctions against any Board of Pharmacy licensee engaged in the compounding or selling of these drug products.

For more information on the FDA's concerns regarding unapproved GLP-1 drugs used for weight

## Be Vigilant - Watch Out for Scammers!

**BOARD STAFF DO NOT ASK FOR MONEY OVER THE PHONE OR VIA EMAIL TO RESOLVE PENDING INVESTIGATIONS. WHEN IN DOUBT, PLEASE CONTACT THE BOARD IF YOU BELIEVE YOU ARE THE TARGET OF A SCAM.**

The Ohio Board of Pharmacy continues to learn that licensees are being targeted by scammers who claim to work for various governmental agencies (Board of Pharmacy, DEA, FBI, Department of Justice, etc.) to obtain money from the target. The Board strongly encourages licensees to be alert to avoid scammers.

Scammers may try to initiate contact via phone calls, emails, faxes, and letters purporting to originate from various state and federal agencies that include allegations of drug trafficking and threats of suspension against the target's license.

Board of Pharmacy investigators will not ask for fine payment or personal/sensitive information over the phone and will never contact licensees via fax. As a reminder, administrative fines issued by the Board are not paid via gift cards or cryptocurrency. If the Board of Pharmacy is conducting an investigation and that individual faces action against their license, they will receive an official notice of opportunity for a hearing either via certified mail, personal service, or electronic registered mail.

If you are contacted by a scammer, please report this information using the Board's online complaint form: [www.pharmacy.ohio.gov/complaint](http://www.pharmacy.ohio.gov/complaint). Additionally, reports should be made to your local law enforcement agency.

If you receive any suspicious calls or correspondence purporting to be from the Board of Pharmacy, we encourage you to call (614-466-4143) or email ([contact@pharmacy.ohio.gov](mailto:contact@pharmacy.ohio.gov)) the Board to confirm its legitimacy.



***People call, text, and chat the 988 Lifeline to talk about a lot of emotional needs—not just thoughts of suicide. Whatever your reason, the #988Lifeline is there to help. There is hope.***

---

Ohio Board of Pharmacy  
**Mike DeWine**, Governor | **Steven W. Schierholt**, Executive Director

Ohio Board of Pharmacy | 77 S. High St 17th Floor | Columbus, OH 43215 US

[Unsubscribe](#) | [Constant Contact Data Notice](#)